Adam Crystal Sells 38,460 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 38,460 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $25.00, for a total transaction of $961,500.00. Following the transaction, the insider directly owned 112,622 shares in the company, valued at approximately $2,815,550. This trade represents a 25.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Adam Crystal also recently made the following trade(s):

• On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $21.20, for a total transaction of $572,400.00.
• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $20.11, for a total transaction of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $303,765.00.
• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total transaction of $226,221.52.

Tango Therapeutics Trading Down 1.1%

Shares of NASDAQ:TNGX traded down $0.29 on Thursday, reaching $25.04. 2,427,370 shares of the company were exchanged, compared to its average volume of 3,009,367. Tango Therapeutics, Inc. has a 1-year low of $1.03 and a 1-year high of $26.00. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -28.78 and a beta of 1.31. The company has a 50-day moving average of $16.94 and a 200-day moving average of $12.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. As a group, analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on TNGX shares. Piper Sandler boosted their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Mizuho boosted their price objective on shares of Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 11th. Guggenheim boosted their price objective on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Wall Street Zen lowered shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Stifel Nicolaus boosted their price objective on shares of Tango Therapeutics from $15.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the 4th quarter valued at about $35,000. Dynamic Technology Lab Private Ltd lifted its holdings in Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc lifted its holdings in Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after purchasing an additional 4,464 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in Tango Therapeutics in the 4th quarter valued at about $40,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.